Todays challenges in pharmacovigilance: What can we learn from epoetins?

Drug Safety

Volumn 34, Issue 4, 2011, Pages 273-287

  Ebbers, Hans C ^a   Mantel Teeuwisse, Aukje K ^a,b   Moors, Ellen H M ^c   Schellekens, Huub ^a,c   Leufkens, Hubert G ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b MEDICINES EVALUATION BOARD   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Adverse reaction monitoring; Epoetin alfa, adverse reactions; Erythropoiesis stimulants, adverse reactions; Legislation; Postmarketing surveillance; Pure red cell aplasia, drug induced; Tumours, drug induced.

Indexed keywords

ERYTHROPOIETIN ANTIBODY; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANTIBODY PRODUCTION; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CREUTZFELDT JAKOB DISEASE; DRUG APPROVAL; DRUG FORMULATION; DRUG LEGISLATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ERYTHROPOIESIS; HUMAN; HYPERTENSION; IMMUNOGENICITY; PRIORITY JOURNAL; PRODUCT RECALL; PURE RED CELL ANEMIA; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOSIS; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; EUROPE; GOVERNMENT REGULATION; IMMUNOLOGY; NEOPLASM; STANDARD; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANIMALS; DISEASE PROGRESSION; ERYTHROPOIETIN, RECOMBINANT; EUROPE; GOVERNMENT REGULATION; HUMANS; NEOPLASMS; RED-CELL APLASIA, PURE; UNITED STATES;

EID: 79952768939     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11586350-000000000-00000     Document Type: Review

References (82)

1. Singh D. Merck withdraws arthritis drug worldwide. BMJ 2004 Oct 9; 329 (7470): 816.
2. Charatan F. Bayer decides to withdraw cholesterol lowering drug. BMJ 2001 Aug 18; 323 (7309): 359a.
3. Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003 Jan-Feb; 12 (1): 17-29. (Pubitemid 36192946)
4. Cohen D. Rosiglitazone: what went wrong? BMJ 2010; 341: c4848.
5. Edwards IR. What are the real lessons from Vioxx?Drug Saf 2005; 28 (8): 651-8. (Pubitemid 41132453)
6. Lenzer J. FDA is incapable of protecting US 'against another Vioxx'. BMJ 2004 Nov 27; 329 (7477): 1253.
7. Fraunhofer Institute for Systems and Innovation Research (ISI). Assessment of the European community system of pharmacovigilance. Karlsruhe: Fraunhofer Institute, 2006.
8. Furberg CD, Levin AA, Gross PA, et al. The FDA and drug safety: a proposal for sweeping changes. Arch Intern Med 2006 Oct 9; 166 (18): 1938-42. (Pubitemid 44537173)
9. Eichler HG, Abadie E, Raine JM, et al. Safe drugs and the cost of good intentions.NEngl J Med 2009 Apr 2; 360 (14): 1378-80.
10. European Commission. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use [online]. Available from URL: http://ec.europa.eu/health/files/eudralex/vol-1/dir-2004-27/dir-2004-27-en.pdf [Accessed 2010 Dec 15]
11. European Commission Regulation (EC) No 726/ 2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency [online]. Available from URL: http://ec.europa.eu/ health/files/eudralex/vol-1/reg-2004-726-cons/ reg-2004-726-cons-en.pdf [Accessed 2010 Dec 15].
12. Food and Drug Administration, Guidance for industry: format and content of proposed risk evaluation and mitigation strategies (REMS) REMS assessments and proposed REMS modifications, Draft guidance, 2009; Sep [online], http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ UCM184128.pdf [Accessed 2010 Jun 1].
13. Faden LB, Milne CP. Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution? Food Drug Law J 2008; 63 (3): 683-700.
14. European Commission.Directive 2010/84/ECof theEuropean Parliament and of the Council of 15 December 2010 amendingDirective 2001/83/EC on the Community code relating to medicinal products for human use [online]. Available from URL: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do? uri=OJ:L:2010:348:0074:0099: EN:PDF [Accessed 2011 Mar 14].
15. Food and Drug Administration. The Sentinel Initiative: a national strategy for monitoring medical product safety. Silver Spring (MD): Food and Drug Administration, 2008.
16. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). What is ENCePP? [online]. Available from URL: http://www.encepp.eu/ structure/index.html [Accessed 2009 Sep 24].
17. Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance: lack of vigilance, lack of trust. JAMA 2004 Dec 1; 292 (21): 2647-50. (Pubitemid 39577521)
18. Avorn J, Schneeweiss S. Managing drug-risk information: what to do with all those new numbers. N Engl JMed 2009 Aug 13; 361 (7): 647-9.
19. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009 Nov 19; 361 (21): 2019-32.
20. Eschbach JW,Abdulhadi MH, Browne JK, et al.Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med 1989 Dec 15; 111 (12): 992-1000. (Pubitemid 20034923)
21. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008 Feb 27; 299 (8): 914-24. (Pubitemid 351397066)
22. Gascó n P, Evaluating erythropoietic agents for the treatment of anaemia in the oncology setting. Eur J Cancer, 2005, 41 (17)2601-12.
23. Aranesp- (darbepoetin alfa): prescribing information. Thousand Oaks (CA): Amgen, 2002.
24. Sunder-Plassmann G, Hö rl WH. Effect of erythropoietin on cardiovascular diseases. Am J Kidney Dis 2001; 38 (4 Suppl. 1): S20-5. (Pubitemid 32927606)
25. Glaspy JA. Erythropoietin in cancer patients. Annu Rev Med 2009; 60: 181-92.
26. McKoy JM, Stonecash RE, Cournoyer D, et al. Epoetinassociated pure red cell aplasia: past, present, and future considerations. Transfusion 2008 Aug; 48 (8): 1754-62.
27. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002 Feb 14; 346 (7): 469-75. (Pubitemid 34441737)
28. Casadevall N, Dupuy E, Molho-Sabatier P, et al. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996 Mar 7; 334 (10): 630-3. (Pubitemid 26072120)
29. Bergrem H, Danielson BG, Eckardt KU, et al. A case of antierythropoietin antibodies following recombinant human erythropoietin treatment. In: Bauer C, KochKM, Scigalla P, et al., editors. Erythropoietin: molecular physiology and clinical applications. New York:Marcel Dekker, 1993.
30. Peces R, de la Torre M, Alcazar R, et al. Antibodies against recombinant human erythropoietin in a patient with erythropoietin- resistant anemia. N Engl J Med 1996 Aug 15; 335 (7): 523-4. (Pubitemid 26269960)
31. Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 1997 May; 47 (5): 331-5. (Pubitemid 27230631)
32. Schellekens H, Jiskoot W. Erythropoietin-associated PRCA: still an unsolved mystery. J Immunotoxicol 2006 Sep 1; 3 (3): 123-30. (Pubitemid 44266961)
33. Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005 Jun; 67 (6): 2346-53. (Pubitemid 41623396)
34. Rossert J, Muirhead N, White L, et al. An active postmarketing surveillance (PMS) plan to prospectively monitor the incidence of pure red cell aplasia (PRCA) among patients receiving epoetin alfa therapy or other erythropoietins [abstract]. Nephrol Dial Transplant 2006; 21 Suppl. 4: iv153.
35. AnagnostouA, Lee ES,KessimianN, et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990 Aug; 87 (15): 5978-82.
36. Grote T, Yeilding AL, Castillo R, et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2005 Dec 20; 23 (36): 9377-86.
37. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003 Oct 18; 362 (9392): 1255-60. (Pubitemid 37324251)
38. Dubray B, Mosseri V, Brunin F, et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 1996 Nov; 201 (2): 553-8. (Pubitemid 26357660)
39. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005 Sep 1; 23 (25): 5960-72.
40. Untch M, Fasching PA, Bauerfeind I, et al. PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/ cyclophosphamide followed by paclitaxel darbepoetin alfa in primary breast cancer: a preplanned interim analysis of efficacy at surgery. J Clin Oncol 2008 May 20; 26 (15 Suppl.): 517.
41. Oncologic Drugs Advisory Committee. FDA briefing document. 2008 Mar 13. Silver Spring (MD): FDA [online]. Available fromURL: http://www.fda.gov/ohrms/ dockets/ac/ 08/briefing/2008-4345b2-01-FDA.pdf [Accessed 2011 Feb 17].
42. European Medicines Agency. EMEA recommends a new warning for epoetins for their use in cancer patients [press release]. 2008 Jun 26 [online]. Available from URL: http:// www.emea.europa.eu/pdfs/human/press/pr/33396308en.pdf [Accessed 2010 Dec 15].
43. Procrit label/Epogen label [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/ 103234s5164lbl.pdf2008 [Accessed 2009 Jun 3].
44. Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or darbepoetin for patients with cancer: meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009; (3): CD007303.
45. Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 2007 Jun 14; 356 (24): 2445-8. (Pubitemid 46919767)
46. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94: 1211-20. (Pubitemid 34993871)
47. Caro JJ, Maribel S, Alexandra W, et al. Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 2001; 91 (12): 2214-21. (Pubitemid 32552805)
48. Newland AM, Black CD. Tumor progression associated with erythropoiesis-stimulating agents. Ann Pharmacother 2008; 42 (12): 1865-70.
49. Bohlius J,Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006 May 17; 98 (10): 708-14. (Pubitemid 43821788)
50. Adamson JW. Erythropoietic-stimulating agents: the cancer progression controversy and collateral damage to the blood supply. Transfusion 2009; 49 (5): 824-6.
51. Weinberg PD, Hounshell J, Sherman LA, et al. Legal, financial, and public health consequences of HIV contamination of blood and blood products in the 1980s and 1990s. Ann Intern Med 2002 Feb 19; 136 (4): 312-9. (Pubitemid 34150760)
52. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009 Apr 9; 113 (15): 3406-17.
53. Muirhead N, Bargman J, Burgess E, et al. Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 1995; 26 (2 Suppl. 1): S1-24.
54. Levin A, Beaulieu MC. TREAT: implications for guideline updates and clinical care.AmJKidneyDis 2010; 55 (6): 984-7.
55. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006 Nov 16; 355 (20): 2085-98. (Pubitemid 44749317)
56. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002 Oct 1; 20 (19): 4083-107.
57. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008 Jan 1; 26 (1): 132-49.
58. Meyboom RH, Olsson S. Pharmacovigilance. In: Mulder GJ, Dencker L, editors. Pharmaceutical toxicology. London: Pharmaceutical Press, 2006: 229-41.
59. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf 2005; 28 (10): 851-70. (Pubitemid 41428543)
60. Marmont A, Peschle C, Sanguineti M, et al. Pure red cell aplasia (PRCA): response of three patients of cyclophosphamide and/or antilymphocyte globulin (ALG) and demonstration of two types of serum IgG inhibitors to erythropoiesis. Blood 1975 Feb 1; 45 (2): 247-61.
61. Casati S, Passerini P, Campise MR, et al. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. BMJ (Clin Res Ed) 1987 Oct 24; 295 (6605): 1017-20. (Pubitemid 17151250)
62. Collins AJ, Li S, Adamson JW, et al. Assessment of pure red cell aplasia in US dialysis patients: the limits of the Medicare data. Am J Kidney Dis 2004 Mar; 43 (3): 464-70. (Pubitemid 38298205)
63. Rades D, Schild SE, Yekebas EF, et al. Epoetin-alpha during radiotherapy for stage III esophageal carcinoma. Cancer 2005 Jun 1; 103 (11): 2274-9.
64. Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001 Jul 1; 50 (3): 705-15. (Pubitemid 32519598)
65. Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS Medicine 2008 Mar 11; 5 (3): e67.
66. Egberts TC. Signal detection: historical background. Drug Saf 2007; 30 (7): 607-9. (Pubitemid 47037320)
67. Platt R, Wilson M, Chan KA, et al. The new Sentinel Network: improving the evidence of medical-product safety. N Engl J Med 2009 Aug 13; 361 (7): 645-7.
68. Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotech 2007; 25 (5): 555-61. (Pubitemid 46834844)
69. Clarke A, Deeks JJ, Shakir SA. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets. Drug Saf 2006; 29 (2): 175-81. (Pubitemid 43213891)
70. European Medicines Agency. Questions and answers on the recommendation to suspend the marketing authorisation for Raptiva [online]. Available from URL: http://www. emea.europa.eu/humandocs/PDFs/EPAR/raptiva/Raptiva Q&A-1552509en.pdf [Accessed 2010 Dec 15].
71. Hauben M, Aronson JK. Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore. Drug Saf 2007; 30 (8): 645-55. (Pubitemid 47295824)
72. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58 (5): 295-300.
73. Steinbrook R. Haemoglobin concentrations in chronic kidney disease. Lancet 2006 Dec 23; 368 (9554): 2191-3. (Pubitemid 44958992)
74. Arbuckle RB, Griffith NL, Iacovelli LM, et al. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policyguided health care. Pharmacotherapy 2008 May; 28 (5 Pt 2): 1-15S.
75. Bennett CL, Nebeker JR, Lyons EA, et al. The Research on Adverse Drug events And Reports (RADAR) project. JAMA 2005 May 4; 293 (17): 2131-40. (Pubitemid 40617066)
76. Mackey AC, Green L, Liang L-C, et al. Hepatosplenic T-cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44 (2): 265-7. (Pubitemid 46175082)
77. Pelosini M, Focosi D, Rita F, et al. Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature. Ann Hematol 2008; 87 (5): 405-12.
78. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide: the FDA's review of a new antidiabetic therapy. N Engl J Med 2010 Mar 4; 362 (9): 774-7.
79. Valerie B, Emily B, Gillian R. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360 (9337): 942-4.
80. European Medicines Agency. Public statement on Acomplia: withdrawal of the marketing authorisation in the European Union [online]. Available from URL: http:// www.ema.europa.eu/humandocs/PDFs/EPAR/acomplia/ 3945709en.pdf [Accessed 2010 Jun 29].
81. Tuffs A. German agency suspects that insulin analogue glargine increases risk of cancer. BMJ 2009; 339: b2774.
82. Wise L, Parkinson J, Raine J, et al. New approaches to drug safety: a pharmacovigilance tool kit. Nat Rev 2009 Oct; 8 (10): 779-82